All the latest news and updates about GLP-1 Drugs
The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.